Literature DB >> 19447873

Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression.

Xuefeng Lu1, Xiujing Feng, Xiaobo Man, Guang Yang, Liang Tang, Dan Du, Fan Zhang, Haixin Yuan, Qin Huang, Zhe Zhang, Yinkun Liu, Dennis Strand, Zhengjun Chen.   

Abstract

PURPOSE: Lethal giant larvae functions as a cell polarity regulator and a tumor suppressor in Drosophila. Its evolutionary conservation implies a tumor suppressor role for its human homologue, Hugl-1. The aims of this study were to characterize Hugl-1 and to determine the clinical significance of Hugl-1 alterations in hepatocellular carcinoma (HCC). EXPERIMENTAL
DESIGN: Sequence alterations of Hugl-1 from 80 HCC specimens and 5 HCC cell lines were characterized by reverse transcription-PCR and sequence analysis. Western blot was used for determining Hugl-1 expression. The biological activities of Hugl-1 and its aberrant variants were examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, wound healing assay, Boyden chamber assay, and tumorigenicity assay.
RESULTS: In 32.5% (26 of 80) of the specimens and 20.0% (one of five) of HCC cell lines, 23 unique aberrant Hugl-1 transcripts were identified, most of which resulted from skipping part of and/or entire exon or insertion of intron sequences. The majority of these aberrant Hugl-1 transcripts encoded truncated proteins lacking one or more conserved WD-40 repeat motifs. Two truncated Hugl-1 proteins were found exclusively in HCC tissues. Aberrant Hugl-1 transcripts (78.3%, 20 of 23) had a short "direct repeat" sequence flanking their deleted regions. The abnormal Hugl-1 was significantly correlated with poor differentiation and large tumor size of HCC. Overexpression of two representative HCC-derived aberrant Hugl-1 variants promoted HCC cell migration, invasion, and tumorigenicity in nude mice.
CONCLUSIONS: We provide the first evidence that Hugl-1 mRNA is frequently mutated by aberrant splicing exclusively in HCC, which may be involved in HCC progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447873     DOI: 10.1158/1078-0432.CCR-08-2078

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

Review 1.  Epithelial cell polarity, stem cells and cancer.

Authors:  Fernando Martin-Belmonte; Mirna Perez-Moreno
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

Review 2.  Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment.

Authors:  Danila Coradini; Claudia Casarsa; Saro Oriana
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 3.  Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.

Authors:  Carmen Berasain; Saioa Goñi; Josefa Castillo; María Ujue Latasa; Jesús Prieto; Matías A Avila
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

4.  Deregulation of the cell polarity protein Lethal giant larvae 2 (Lgl2) correlates with gastric cancer progression.

Authors:  Kyung Han Nam; Min A Kim; Gheeyoung Choe; Woo Ho Kim; Hye Seung Lee
Journal:  Gastric Cancer       Date:  2013-12-13       Impact factor: 7.370

5.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

6.  NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Authors:  Sophia Adamia; Michal Bar-Natan; Benjamin Haibe-Kains; Patrick M Pilarski; Christian Bach; Samuel Pevzner; Teresa Calimeri; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; Ilene Galinsky; Steven Mathews; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Daniel G Tenen; Richard M Stone; James D Griffin
Journal:  Blood       Date:  2014-02-26       Impact factor: 22.113

Review 7.  Cell polarity as a regulator of cancer cell behavior plasticity.

Authors:  Senthil K Muthuswamy; Bin Xue
Journal:  Annu Rev Cell Dev Biol       Date:  2012-08-06       Impact factor: 13.827

Review 8.  Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators.

Authors:  Ling Huang; Senthil K Muthuswamy
Journal:  Curr Opin Genet Dev       Date:  2010-01-21       Impact factor: 5.578

9.  Hugl-1 induces apoptosis in esophageal carcinoma cells both in vitro and in vivo.

Authors:  Jia Song; Xiu-Lan Peng; Meng-Yao Ji; Ming-Hua Ai; Ji-Xiang Zhang; Wei-Guo Dong
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

Review 10.  Lessons from development: A role for asymmetric stem cell division in cancer.

Authors:  Anne E Powell; Chia-Yi Shung; Katherine W Saylor; Karin A Müllendorff; Karin A Müllendorf; Joseph B Weiss; Melissa H Wong
Journal:  Stem Cell Res       Date:  2009-09-25       Impact factor: 2.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.